Yahoo Finance

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today ...
Yahoo Finance

Inflammasome Therapeutics to Collaborate with Sean M. Healey & AMG Center for ALS on a new treatment for Amyotrophic Lateral Sclerosis (ALS)

NEWTON, Mass., November 13, 2025--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and ...
Hosted on MSN

Tiziana Life Sciences’ Nasal Foralumab Trial Joins ALS MyMatch Program

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Finanznachrichten

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

BOSTON, Nov. 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal ...
Proactiveinvestors

Tiziana Life Sciences’ Phase 2 foralumab trial joins Healey ALS MyMatch Program

Investigational products showing positive results in the Healey ALS MyMatch program may advance to the HEALEY ALS Platform Trial or proceed directly to standalone Phase 3 trials. ALS is a ...